Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00860067 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

A Phase 2 study of Healthy or Stable Underlying Chronic Medical Condition, sponsored by MedImmune.

Completed
Registry status
Phase 2
Development phase
1,800
Enrollment target
18
Study locations

NCT00860067 is a Phase 2 study of Healthy or Stable Underlying Chronic Medical Condition that has completed, run by MedImmune. The registered enrollment target is 1,800 participants. The trial reports 18 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00860067, a Phase 2 study of Healthy or Stable Underlying Chronic Medical Condition, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 2
Development phase
1,800 participants
Enrollment target
18
Study locations

Study Summary

The objective of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI3250) produced antibody levels similar to those produced by the commercial vaccine, FluMist.

Interventions

  • BIOLOGICAL Q/LAIV (MEDI3250)
  • BIOLOGICAL FluMist/B/Yamagata
  • BIOLOGICAL FluMist/B/Victoria

Study Locations (18)

Florida

  • University Clinical Research-Deland, LLC - DeLand
  • Pharmax Research Clinic, Inc - Miami
  • University Clinical Research, Inc - Pembroke Pines
  • Miami Research Associates - South Miami

California

  • Benchmark Research - Sacramento
  • California Research Foundation - San Diego
  • Benchmark Research - San Francisco

Missouri

  • The Center for Pharmaceutical Research, PC - Kansas City
  • Sundance Clinical Research - St Louis

Texas

  • Benchmark Research - Austin
  • Benchmark Research - Fort Worth

Georgia

  • Clinical Research Atlanta - Stockbridge

Kansas

  • Vince and Associates Clinical Research - Overland Park

Kentucky

  • Kentucky Pediatric / Adult Research - Bardstown

Nebraska

  • Meridian Clinical Research, LLC - Omaha

Trial Details

FieldValue
Enrollment Target 1,800 participants
Start Date 2009-03
Est. Completion 2009-10
Phase Phase 2

Sponsor

MedImmune

210 total trials

What the Registry Record Tells You About NCT00860067

The ClinicalTrials.gov registry entry for NCT00860067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy or Stable Underlying Chronic Medical Condition appearing as the primary indexed condition, and to 3 interventions - of which Q/LAIV (MEDI3250) is the first listed.

NCT00860067 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT00860067 about?

NCT00860067 is a clinical study titled "A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age". The objective of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI3250) produced antibody levels similar to those produced by the commercial vaccine, FluMist.

What is the current status of trial NCT00860067?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,800 participants. The study started on 2009-03. Estimated completion is 2009-10.

What conditions does trial NCT00860067 study?

This clinical trial studies the following conditions: Healthy or Stable Underlying Chronic Medical Condition.

What interventions are being tested in trial NCT00860067?

The interventions under investigation include: Q/LAIV (MEDI3250) (BIOLOGICAL), FluMist/B/Yamagata (BIOLOGICAL), FluMist/B/Victoria (BIOLOGICAL).

Who is sponsoring clinical trial NCT00860067?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00860067 being conducted?

This trial has 18 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.